MD MBA - Assertio Therapeutics Senior Medical

ASRT Stock  USD 1.01  0.07  7.45%   

Executive

MD MBA is Senior Medical of Assertio Therapeutics
Address 100 South Saunders Road, Lake Forest, IL, United States, 60045
Phone224 419 7106
Webhttps://www.assertiotx.com

Assertio Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.0144) % which means that it has lost $0.0144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4236) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.8 in 2024. Return On Capital Employed is likely to gain to -1.2 in 2024. Liabilities And Stockholders Equity is likely to gain to about 336.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 72.3 M in 2024.
Assertio Therapeutics currently holds 40.91 M in liabilities with Debt to Equity (D/E) ratio of 0.49, which is about average as compared to similar companies. Assertio Therapeutics has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Assertio Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Christopher MutzANI Pharmaceuticals
53
Matt AugustsonLifecore Biomedical
N/A
Kristen JDPacira BioSciences,
50
Lauren RikerPacira BioSciences,
45
Thomas RowlandANI Pharmaceuticals
57
John MBACatalent
69
Gregory SgammatoAmneal Pharmaceuticals, Class
N/A
Michael MDIronwood Pharmaceuticals
65
Charles LaranjeiraPacira BioSciences,
58
Steve LaningaLifecore Biomedical
N/A
Mannam VenkatanarasimhamDr Reddys Laboratories
N/A
Darin LippoldtNeurocrine Biosciences
58
Julie CookeNeurocrine Biosciences
58
Christopher YoungPacira BioSciences,
52
Matthew CPANeurocrine Biosciences
44
Shawn CrossPacira BioSciences,
56
Paul SurdezCatalent
N/A
Sandra CoombsAlkermes Plc
N/A
Tomoko YamagishiDresslerEvolus Inc
N/A
Anil NamboodiripadDr Reddys Laboratories
54
Ori GutwergANI Pharmaceuticals
49
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. Assertio Therapeutics (ASRT) is traded on NASDAQ Exchange in USA. It is located in 100 South Saunders Road, Lake Forest, IL, United States, 60045 and employs 53 people. Assertio Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Assertio Therapeutics Leadership Team

Elected by the shareholders, the Assertio Therapeutics' board of directors comprises two types of representatives: Assertio Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Assertio. The board's role is to monitor Assertio Therapeutics' management team and ensure that shareholders' interests are well served. Assertio Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Assertio Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jack Hoblitzell, VP Operations
MD MBA, Senior Medical
Brendan OGrady, CEO Director
Ajay Patel, VP Officer
Sam Schlessinger, Senior Counsel
Molly Dir, Senior Administration
Bill Iskos, Senior Operations
Paul Schwichtenberg, Senior Officer
Jeff Christensen, Senior Commercial
Heather Mason, Interim Director
Daniel Peisert, CEO Pres

Assertio Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Assertio Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.